ITPKC and Hirschsprung disease: A therapeutic Itpk inhibitor would need to be exquisitely selective for Itpkb to avoid inhibition of Itpkc, whose lof hyperactivates T cells, B cells, and macrophages and has been implicated in human inflammatory KD, Hirschsprung disease, calcium nephrolithiasis, and cervical squamous cell carcinoma (150–152).